ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update
11 mai 2022 16h05 HE
|
ADMA Biologics, Inc.
First Quarter 2022 Total Revenues Were Approximately $29.1 Million, an 81% Increase Over First Quarter 2021 Increases Full Year 2022 Total Revenue Guidance to $130 Million or More From $125...
ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022
04 mai 2022 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022
01 avr. 2022 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., April 01, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 Months
25 mars 2022 07h00 HE
|
ADMA Biologics, Inc.
Approval of 36-month shelf life encompasses all ASCENIV & BIVIGAM vial sizes, production scales, as well as internal and external fill-finishing Extended shelf life ASCENIV & BIVIGAM now...
ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management
24 mars 2022 16h05 HE
|
ADMA Biologics, Inc.
Full Year 2021 Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020 Gross Profitability for Full Year 2021 Driven by Greater Market Penetration of Higher-Margin Product Mix...
ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022
21 mars 2022 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., March 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA
07 mars 2022 16h05 HE
|
ADMA Biologics, Inc.
FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth Company positioned to meet or exceed target of 10 or more FDA-approved plasma collection centers by...
ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update
19 janv. 2022 07h00 HE
|
ADMA Biologics, Inc.
Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception Full Year 2021 Preliminary Unaudited Total...
ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC
18 janv. 2022 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla. and GOOSE CREEK, S.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated...
ADMA Biologics Adopts Limited Duration Stockholder Rights Plan
21 déc. 2021 07h00 HE
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and...